ETON Eton Pharmaceuticals, Inc.
Healthcare$31.29-3.99%ClosedMarket Cap: $857.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
29.05
P/S
10.27
EV/EBITDA
155.37
DCF Value
$-41.59
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.8%
Operating Margin
2.3%
Net Margin
-1.7%
ROE
-5.7%
ROA
-1.5%
ROIC
3.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $24.3M | 60.7% | $2.4M | $1.6M | $— | — |
| Q4 null | $21.3M | 61.6% | $2.5M | $1.5M | $— | — |
| FY null | $80.0M | 53.5% | $72.0K | $-4.6M | $— | — |
| Q3 null | $22.5M | 35.0% | $-1.4M | $-1.9M | $— | — |
| Q2 null | $18.9M | 63.0% | $-1.5M | $-2.6M | $— | — |
| Q1 null | $17.3M | 57.1% | $-470.0K | $-1.6M | $— | — |
| Q4 null | $11.6M | 55.6% | $629.0K | $-598.0K | $— | — |
| FY null | $39.0M | 60.0% | $-2.6M | $-3.8M | $— | — |
| Q3 null | $10.3M | 61.0% | $509.0K | $627.0K | $— | — |
| Q2 null | $9.1M | 62.0% | $-2.9M | $-3.0M | $— | — |
| Q1 null | $8.0M | 62.9% | $-800.0K | $-811.0K | $— | — |
| Q4 2023 | $7.3M | 49.6% | $-2.0M | $-2.3M | $-0.09 | — |